High dose rate brachytherapy versus low dose rate brachytherapy for the treatment of prostate cancer a review of clinical effectiveness and cost-effectiveness
There is not currently direct clinical evidence supporting the superiority of high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy with respect to tumor control or reduced toxicity. Therefore, the purpose of this report is to summarize the evidence regarding the comparative clinical and cost-ef...
| Main Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
February 14, 2019, 2019
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | There is not currently direct clinical evidence supporting the superiority of high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy with respect to tumor control or reduced toxicity. Therefore, the purpose of this report is to summarize the evidence regarding the comparative clinical and cost-effectiveness of HDR versus LDR brachytherapy for the treatment of prostate cancer |
|---|---|
| Physical Description: | 1 PDF file (25 pages) illustrations |